The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 10, 2019

Filed:

Apr. 27, 2016
Applicant:

University of Manitoba, Winnipeg, CA;

Inventors:

Aaron Marshall, Winnipeg, CA;

Sen Hou, Winnipeg, CA;

Assignee:

UNIVERSITY OF MANITOBA, Winnipeg, CA;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/435 (2006.01); A61K 38/17 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01); A01K 67/027 (2006.01); C07K 14/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/435 (2013.01); A01K 67/0275 (2013.01); A01K 67/0276 (2013.01); A61K 38/1709 (2013.01); C07K 14/001 (2013.01); G01N 33/5088 (2013.01); G01N 33/6854 (2013.01); G01N 33/6893 (2013.01); A01K 2217/058 (2013.01); A01K 2217/075 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0387 (2013.01); A61K 38/00 (2013.01); G01N 2333/47 (2013.01); G01N 2333/4721 (2013.01); G01N 2500/00 (2013.01); G01N 2500/10 (2013.01); G01N 2800/18 (2013.01); G01N 2800/347 (2013.01);
Abstract

Provided herein are FDC-SP polypeptides and methods of using such polypeptides. Methods include, but are not limited to, altering IgA concentration in a subject, treating a subject having signs of a disorder that includes excessive IgA production, identifying a compound that decreases the concentration of IgA in an animal, and identifying a compound that treats a condition associated with increased levels of IgA. Also provided herein is an animal that has decreased expression of an endogenous FDC-SP coding sequence. The animal may develop pathophysiological features of IgA nephropathy, and/or may display increased IgA in serum, saliva, bronchoalveolar lavage fluid, or a combination thereof; increased IgA expressing B lymphocytes in circulation, lymphoid tissue, or a combination thereof; or increased IgA production in vitro by isolated B lymphocytes.


Find Patent Forward Citations

Loading…